173 related articles for article (PubMed ID: 27874054)
1. Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.
Yu G; Li Y; Cui Z; Morris NP; Weinberg AD; Fox BA; Urba WJ; Wang L; Hu HM
Sci Rep; 2016 Nov; 6():37558. PubMed ID: 27874054
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell-derived autophagosomes (DRibbles)-activated B cells induce specific naïve CD8
Zhang TY; Ren HY; Pan N; Dong HX; Zhao SM; Wen ZF; Wang XR; Wang LX
Cancer Immunol Immunother; 2021 Feb; 70(2):463-474. PubMed ID: 32809049
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism.
Twitty CG; Jensen SM; Hu HM; Fox BA
Clin Cancer Res; 2011 Oct; 17(20):6467-81. PubMed ID: 21810919
[TBL] [Abstract][Full Text] [Related]
4. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.
Li Y; Wang LX; Pang P; Cui Z; Aung S; Haley D; Fox BA; Urba WJ; Hu HM
Clin Cancer Res; 2011 Nov; 17(22):7047-57. PubMed ID: 22068657
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
Yu G; Moudgil T; Cui Z; Mou Y; Wang L; Fox BA; Hu HM
J Immunother; 2017 Jun; 40(5):155-163. PubMed ID: 28368960
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Antitumor Efficacy of Cancer Stem Cell-Derived DRibble Vaccine on Colorectal Carcinoma.
Fu C; Tian G; Duan J; Liu K; Zhang C; Yan W; Wang Y
Int J Med Sci; 2021; 18(14):3249-3260. PubMed ID: 34400894
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles).
Ren H; Zhao S; Li W; Dong H; Zhou M; Cao M; Hu HM; Wang LX
J Immunother; 2014 Oct; 37(8):383-93. PubMed ID: 25198526
[TBL] [Abstract][Full Text] [Related]
9. GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.
Durham NM; Holoweckyj N; MacGill RS; McGlinchey K; Leow CC; Robbins SH
J Immunother Cancer; 2017; 5():47. PubMed ID: 28649380
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitinated proteins enriched from tumor cells by a ubiquitin binding protein Vx3(A7) as a potent cancer vaccine.
Aldarouish M; Wang H; Zhou M; Hu HM; Wang LX
J Exp Clin Cancer Res; 2015 Apr; 34(1):34. PubMed ID: 25886865
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer.
Su H; Luo Q; Xie H; Huang X; Ni Y; Mou Y; Hu Q
Int J Nanomedicine; 2015; 10():1921-30. PubMed ID: 25792826
[TBL] [Abstract][Full Text] [Related]
12. Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner.
Li W; Zhou M; Ren H; Hu HM; Lu L; Cao M; Wang LX
PLoS One; 2013; 8(1):e53564. PubMed ID: 23326458
[TBL] [Abstract][Full Text] [Related]
13. Tumor-derived autophagosome vaccines combined with immune adjuvants mediate antitumor immune responses via the neoantigen pathway.
Yuan J; Chang Y; Dai Y; Chen Y; Yue R; Zeng L
Neoplasma; 2023 Dec; 70(6):747-760. PubMed ID: 38014701
[TBL] [Abstract][Full Text] [Related]
14. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
15. TLR and NLRP3 inflammasome-dependent innate immune responses to tumor-derived autophagosomes (DRibbles).
Xing Y; Cao R; Hu HM
Cell Death Dis; 2016 Aug; 7(8):e2322. PubMed ID: 27490927
[TBL] [Abstract][Full Text] [Related]
16. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
[TBL] [Abstract][Full Text] [Related]
17. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
20. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
